Oncomatryx Biopharma

Oncomatryx Biopharma company information, Employees & Contact Information

Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.

Company Details

Employees
27
Founded
-
Address
Science And Technology Park Of Bizkaia Building 801b, Derio,bizkaia 48160,spain
Phone
+34 946 087 037
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Derio, Bizkaia
Looking for a particular Oncomatryx Biopharma employee's phone or email?

Oncomatryx Biopharma Questions

News

Oncomatryx Biopharma Awarded €12.5 Million EIC Accelerator Funding to Advance Groundbreaking ADCs - Business Wire

Oncomatryx Biopharma Awarded €12.5 Million EIC Accelerator Funding to Advance Groundbreaking ADCs Business Wire

TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer - PR Newswire Canada

TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer PR Newswire Canada

ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical Trials - Business Wire

ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical Trials Business Wire

Oncomatryx Secures EU Funding to Advance Antibody-Drug Conjugate Platform - European Biotechnology Magazine

Oncomatryx Secures EU Funding to Advance Antibody-Drug Conjugate Platform European Biotechnology Magazine

ONCOMATRYX: €25 Million Raised To Develop Novel ADCs Against The Tumor Microenvironment - Pulse 2.0

ONCOMATRYX: €25 Million Raised To Develop Novel ADCs Against The Tumor Microenvironment Pulse 2.0

Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment - Business Wire

Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment Business Wire

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC - BioSpace

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC BioSpace

Top Oncomatryx Biopharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant